Evidence map›Paper›PMID 39847409›Full record

ArticleThe Journal of clinical endocrinology and metabolism2025

Using a Composite Summary of Daily Sex Hormones to Gauge Time Until Menopause: A Focus on Pregnanediol Glucuronide (PDG).

J F Winkles, Alicia Colvin, Samar R El Khoudary, Nanette Santoro, Mary Sammel, Sybil Crawford

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

J F WinklesEpidemiology Data Center, University of Pittsburgh, Pittsburgh, PA 15260, USA.ORCID 0009-0007-6450-9809
Alicia ColvinGraduate School of Public Health, Epidemiology, University of Pittsburgh, Pittsburgh, PA 15260, USA.ORCID 0000-0001-5638-2747
Samar R El KhoudaryGraduate School of Public Health, Epidemiology, University of Pittsburgh, Pittsburgh, PA 15260, USA.ORCID 0000-0003-2913-0821
Nanette SantoroObstetrics and Gynecology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0001-9096-7490
Mary SammelBiostatistics and Informatics, Colorado School of Public Health, Aurora, CO 80045, USA.ORCID 0000-0003-1248-4199
Sybil CrawfordPreventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA.ORCID 0000-0001-6621-0439

Funding

The Study of Women's Health Across the Nation (SWAN): The Impact of Midlife and the Menopause Transition on Health and Functioning in Early Old AgeU19AG063720 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Maria Mori Brooks · 2024 to 2024
$21.9M
SWAN REPOSITORYU01AG017719 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2000 to 2005
$9.9M
WOMENS HEALTH ACROSS THE NATION--PITTSBURGHU01AG012546 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 1994 to 2005
$8.4M
WOMENS HEALTH ACROSS THE NATION--COORDINATING CENTERU01AG012553 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 1994 to 2005
$7.8M
WOMENS HEALTH ACROSS THE NATION--ENDOCRINE LABU01AG012495 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 1994 to 2005
$7.4M
WOMENS HEALTH ACROSS THE NATION--UCDAVISU01AG012554 · UNIVERSITY OF CALIFORNIA DAVIS · 1994 to 2005
$4.5M
WOMENS HEALTH ACROSS THE NATION--UCLAU01AG012539 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 1994 to 2005
$4.5M
WOMENS HEALTH ACROSS THE NATION--CHICAGOU01AG012505 · RUSH UNIVERSITY MEDICAL CENTER · 1994 to 2005
$4.4M
Women's Health Across the Nation-New Jersey SiteU01AG012535 · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · 1994 to 2005
$4.0M
THE STUDY OF WOMEN'S HEALTH ACROSS THE NATION-MICHIGANU01NR004061 · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 1994 to 2005
$4.0M
WOMENS HEALTH ACROSS THE NATION--MASSACHUSETTS GENERAL HU01AG012531 · MASSACHUSETTS GENERAL HOSPITAL · 1994 to 2005
$3.3M
DHHSNCATS NIH HHSNCRR NIH HHS UL1 RR024131NIA NIH HHS U01 AG012495NIA NIH HHS U01 AG012505NIA NIH HHS U01 AG012531NIA NIH HHS U01 AG012535NIA NIH HHS U01 AG012539NIA NIH HHS U01 AG012546NIA NIH HHS U01 AG012553NIA NIH HHS U01 AG012554NIA NIH HHS U01 AG017719NIA NIH HHS U19 AG063720NIH HHSNIH Office of Research on Women's Health U01AG012495NIH Office of Research on Women's Health U01AG012505NIH Office of Research on Women's Health U01AG012531NIH Office of Research on Women's Health U01AG012535NIH Office of Research on Women's Health U01AG012539NIH Office of Research on Women's Health U01AG012546NIH Office of Research on Women's Health U01AG012553NIH Office of Research on Women's Health U01AG012554NIH Office of Research on Women's Health U01NR004061NIH Office of Research on Women's Health U19AG063720NINR NIH HHS U01 NR004061SWANThe SWAN Repository U01AG017719
6 · The paper itself

Abstract

contextThe timing of a woman's final menstrual period (FMP) in relation to her age is considered a valuable indicator of overall health, being associated with cardiovascular, bone health, reproductive, and general mortality outcomes.

objectiveThis work aimed to evaluate the relationship between hormones and the "time to FMP" when daily hormone trajectories are characterized by their 1) entropy, and 2) deviation from premenopausal/stable cycle patterns (representing a textbook "gold standard"; GS).

methodsAs part of the Study of Women's Health Across the Nation, urinary luteinizing hormone (LH), follicle-stimulating hormone (FSH), estrogen conjugates (E1C), and pregnanediol glucuronide (PDG) were measured daily from a multiracial sample of 549 mid-life women for the duration of one menstrual cycle. Hormone trajectories were mapped onto a plane with axes representing Fuzzy entropy (FuzzEn) and the normalized dynamic time warping distance (DTW) from the GS.

resultsViewing FSH, E1C, PDG, and LH through this lens reveals that, contrary to existing wisdom, PDG stands out as a powerful predictor/descriptor of "time to FMP." Using cluster analyses to discretize PDG on the DTW/FuzzEn plane yields statistically different survival curves, and Cox proportional hazards analyses confirm that this separation persists in the presence of known covariates of FSH, antimüllerian hormone, age, body mass index, financial hardship, smoking status, and cycle length.

conclusionSince PDG is generally not considered a predictor/descriptor of ovarian aging, this work validates the DTW/FuzzEn analytical framework and introduces another metric/hormone to be used in FMP-related preventive care.

Indexed as

Gonadal Steroid HormonesMenopausePregnanediolAdultFemaleFollicle Stimulating HormoneHumansLuteinizing HormoneMenstrual CycleMiddle AgedTime FactorsFollicle Stimulating HormoneGonadal Steroid HormonesLuteinizing HormonePregnanediolpregnanediol-3 alpha-glucuronidedynamic time warpingentropyfinal menstrual periodmenopauseovarian agingpregnanediol glucuronide (PDG)

Identifiers

PMID39847409
PMCPMC12448593

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.